Fluticasone furoate

Fluticasone furoate

Systematic (IUPAC) name
(6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	C for Intranasal
Legal status	UK: POM (Prescription only) US: ℞-only
Routes of administration	Intranasal
Pharmacokinetic data
Bioavailability	0.51% (Intranasal)
Protein binding	91%
Metabolism	Intranasal Hepatic (CYP3A4-mediated)
Biological half-life	10 hours
Excretion	Renal
Identifiers
CAS Number	80474-14-2
ATC code	R01AD12 (WHO) R03BA09
PubChem	CID: 9854489
DrugBank	DB00588
ChemSpider	8030195
UNII	JS86977WNV Y
ChEBI	CHEBI:74899
ChEMBL	CHEMBL1676
Chemical data
Formula	C27H29F3O6S
Molecular mass	538.576 g/mol
SMILES C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
InChI InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1 Key:XTULMSXFIHGYFS-VLSRWLAYSA-N

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, and South Korea) for the treatment of allergic rhinitis. It is marketed under the name Furamist in India by Cipla. In India it is also marketed by Dr Reddys under the trade name Ennhale. It can be administered by a nasal spray.

The combination drug fluticasone furoate/vilanterol is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.

See also

• Fluticasone
• Fluticasone propionate
• Fluticasone furoate/vilanterol